株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

難治性慢性リンパ性白血病:パイプライン製品の分析

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 251633
出版日 ページ情報 英文 266 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
難治性慢性リンパ性白血病:パイプライン製品の分析 Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2016
出版日: 2016年11月23日 ページ情報: 英文 266 Pages
概要

治療に反応しない白血病は、難治性の慢性リンパ性白血病(CLL)と呼ばれます。発熱と感染症、異常出血、息切れ、体重減少、リンパ節の腫れなどの症状が見られます。治療には、幹細胞移植/骨髄移植が含まれます。

当レポートでは、難治性慢性リンパ性白血病に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

難治性慢性リンパ性白血病 (CLL)の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

難治性慢性リンパ性白血病 (CLL):企業で開発中の治療薬

難治性慢性リンパ性白血病 (CLL):大学/機関で研究中の治療薬

難治性慢性リンパ性白血病 (CLL):パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

難治性慢性リンパ性白血病 (CLL):企業で開発中の製品

難治性慢性リンパ性白血病 (CLL):大学/機関で研究中の製品

難治性慢性リンパ性白血病 (CLL)の治療薬開発に従事している企業

  • 4SC AG
  • AbbVie Inc.
  • Arno Therapeutics, Inc.
  • アステラス製薬
  • Astex Pharmaceuticals, Inc.
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Cellular Biomedicine Group, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Hutchison MediPharma Limited
  • ImmunoGen, Inc.
  • Immunomedics, Inc.
  • Incyte Corporation
  • Infinity Pharmaceuticals, Inc.
  • Innate Pharma S.A.
  • Juno Therapeutics Inc.
  • Karyopharm Therapeutics, Inc.
  • Les Laboratoires Servier SAS
  • LFB S.A.
  • Lymphocyte Activation Technologies, S.A.
  • Medicenna Therapeutics, Inc.
  • Millennium Pharmaceuticals, Inc.
  • MorphoSys AG
  • Novartis AG
  • Oncternal Therapeutics, Inc.
  • Ono Pharmaceutical Co., Ltd.
  • Portola Pharmaceuticals, Inc.
  • Sanofi
  • TG Therapeutics, Inc.
  • Threshold Pharmaceuticals, Inc.
  • Tragara Pharmaceuticals, Inc.

難治性慢性リンパ性白血病 (CLL):治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

難治性慢性リンパ性白血病 (CLL):最近のパイプライン動向

難治性慢性リンパ性白血病 (CLL):休止中のプロジェクト

難治性慢性リンパ性白血病 (CLL):開発が中止された製品

難治性慢性リンパ性白血病 (CLL):製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8687IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2016, provides an overview of the Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline landscape.

Leukemia that does not responded to treatment is called refractory chronic lymphocytic leukemia. Symptoms include fever and infection, abnormal bleeding, shortness of breath, weight loss and swelling of lymph nodes. Treatment includes stem cell transplantation or bone marrow transplantation.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 21, 16 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.Refractory Chronic Lymphocytic Leukemia (CLL).

Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Refractory Chronic Lymphocytic Leukemia (CLL) Overview
  • Therapeutics Development
    • Pipeline Products for Refractory Chronic Lymphocytic Leukemia (CLL) - Overview
    • Pipeline Products for Refractory Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development
    • 4SC AG
    • AbbVie Inc
    • Arno Therapeutics, Inc.
    • Astellas Pharma Inc.
    • Astex Pharmaceuticals Inc
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Celgene Corporation
    • Cellular Biomedicine Group, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Gilead Sciences, Inc.
    • Hutchison MediPharma Limited
    • ImmunoGen, Inc.
    • Immunomedics, Inc.
    • Incyte Corporation
    • Innate Pharma S.A.
    • Juno Therapeutics Inc.
    • Karyopharm Therapeutics, Inc.
    • LFB S.A.
    • Lymphocyte Activation Technologies, S.A.
    • Medicenna Therapeutics, Inc.
    • Millennium Pharmaceuticals Inc
    • MorphoSys AG
    • Novartis AG
    • Oncternal Therapeutics, Inc.
    • Ono Pharmaceutical Co., Ltd.
    • Portola Pharmaceuticals, Inc.
    • Sanofi
    • Tragara Pharmaceuticals, Inc.
    • Verastem, Inc.
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (dezapelisib + itacitinib adipate) - Drug Profile
    • 4SC-202 - Drug Profile
    • acalabrutinib - Drug Profile
    • ACP-319 - Drug Profile
    • afuresertib hydrochloride - Drug Profile
    • AGS-67E - Drug Profile
    • AR-42 - Drug Profile
    • AT-7519 - Drug Profile
    • atezolizumab - Drug Profile
    • BI-836826 - Drug Profile
    • BMS-986016 - Drug Profile
    • buparlisib hydrochloride - Drug Profile
    • CBM-C19.1 - Drug Profile
    • CBM-C20.1 - Drug Profile
    • CC-122 - Drug Profile
    • Cellular Immunotherapy for Chronic Lymphocytic Leukaemia - Drug Profile
    • Cellular Immunotherapy to Target Receptor Tyrosine Kinase-Like Orphan Receptor 1 for Chronic Lymphocytic Leukemia - Drug Profile
    • cerdulatinib - Drug Profile
    • duvelisib - Drug Profile
    • HMPL-523 - Drug Profile
    • idelalisib - Drug Profile
    • IMGN-529 - Drug Profile
    • IMMU-114 - Drug Profile
    • JCAR-014 - Drug Profile
    • JCAR-015 - Drug Profile
    • lirilumab - Drug Profile
    • MDNA-56 - Drug Profile
    • monalizumab - Drug Profile
    • MOR-208 - Drug Profile
    • nivolumab - Drug Profile
    • obinutuzumab - Drug Profile
    • PCAR-019 - Drug Profile
    • PCAR-119 - Drug Profile
    • pilaralisib - Drug Profile
    • S-055746 - Drug Profile
    • selinexor - Drug Profile
    • spebrutinib besylate - Drug Profile
    • TAK-659 - Drug Profile
    • TG-02 - Drug Profile
    • tisagenlecleucel-T - Drug Profile
    • ublituximab - Drug Profile
    • UC-961 - Drug Profile
    • ulocuplumab - Drug Profile
    • urelumab - Drug Profile
    • venetoclax - Drug Profile
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Dormant Projects
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Discontinued Products
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL), H2 2016
  • Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by 4SC AG, H2 2016
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc, H2 2016
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Arno Therapeutics, Inc., H2 2016
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astellas Pharma Inc., H2 2016
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astex Pharmaceuticals Inc, H2 2016
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celgene Corporation, H2 2016
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cellular Biomedicine Group, Inc., H2 2016
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Gilead Sciences, Inc., H2 2016
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hutchison MediPharma Limited, H2 2016
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by ImmunoGen, Inc., H2 2016
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immunomedics, Inc., H2 2016
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Incyte Corporation, H2 2016
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innate Pharma S.A., H2 2016
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Juno Therapeutics Inc., H2 2016
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Karyopharm Therapeutics, Inc., H2 2016
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by LFB S.A., H2 2016
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Lymphocyte Activation Technologies, S.A., H2 2016
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Medicenna Therapeutics, Inc., H2 2016
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by MorphoSys AG, H2 2016
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Novartis AG, H2 2016
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Oncternal Therapeutics, Inc., H2 2016
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Portola Pharmaceuticals, Inc., H2 2016
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sanofi, H2 2016
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Tragara Pharmaceuticals, Inc., H2 2016
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Verastem, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H2 2016
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..1), H2 2016
  • Refractory Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL), H2 2016
  • Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top